[Bone risk of hormone-suppressing therapy in differentiated thyroid epithelioma. Study by dual photon absorptiometry].
A decreased bone mineral density is a well known complication of thyrotoxicosis. If bone is also adversely affected by a subclinical hyperthyroidism is still debated. Such a situation is deliberately induced for treatment of thyroid differentiated carcinoma. We compared bone mineral measurements in case of thyroid carcinoma exposed to prolonged suppressive hormonal treatment (288 patient year, LT3 in 87%) and in age and weight matched controls. We did not find any difference in both sexes between the two populations in term of fracture rate and vertebral mineral density measured by dual photon absorptiometry, nor any influence of gonadal status in women.
Leprat
F
F
Service d'endocrinologie, Hôpital Haut Lévèque, Pessac.
Austyn
C
C
Commenges-Ducos
M
M
Commenges
D
D
Cochet
C
C
Basse-Catalinat
B
B
Ducassou
D
D
Latapie
J L
JL
D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density; D002277:Carcinoma / Q000188:drug therapy* / Q000503:physiopathology* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D011184:Postoperative Period; D012307:Risk Factors; D013963:Thyroid Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology* / Q000601:surgery
D013963:Thyroid Hormones
Risque osseux de l'opothérapie freinatrice dans l'épithélioma différencié de la thyroïde. Etude par absorptiométrie biphotonique.